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ABSTRAK
Latar belakang: Indonesia adalah negara dengan prevalensi tuberkulosis (TB) tertinggi kedua di dunia. 
Karena itu, sangat membutuhkan perbaikan dan inovasi atas strategi yang diterapkan di seluruh wilayah. Satu 
langkah mendasar dalam memantau penerapan ini adalah menyiapkan alat yang divalidasi untuk mengukur total 
biaya pasien dan total biaya bencana. Organisasi Kesehatan Dunia (WHO) merekomendasikan menggunakan 
versi kuesioner generik yang telah disesuaikan dengan konteks budaya lokal untuk menafsirkan temuan 
dengan benar. Tujuan penelitian ini adalah mengadaptasi kuesioner “the Tool to Estimate Patient Costs” 
untuk menghitung biaya total dan biaya total katastrofik pada rumah tangga terdampak tuberkulosis (TB) 
di Indonesia. Metode: Perangkat tersebut diadaptasi sesuai panduan terstruktur. Berdasarkan ujicoba yang 
dilakukan pada studi sebelumnya (dinamakan sebagai ‘Studi Fase 1’). Kami mengembangkan proses adaptasi 
dengan membandingkannya dengan kuesioner generik yang dikeluarkan oleh WHO serta mengevaluasinya 
dalam pertemuan komite pakar. Kami melakukan uji coba pada 30 pasien TB, menerima umpan balik kemudian 
melengkapinya dengan lembar penjelasan sebelum finalisasi kuesioner. Hasil: tujuh puluh dua perubahan mayor 
dilakukan selama proses adaptasi, termasuk mengubah pilihan jawaban agar sesuai dengan konteks Indonesia, 
memperbaiki alur pertanyaan, menghapus pertanyaan, mengubah susunan kata dan mengembalikan pertanyaan 
asli yang diubah sebelumnya di Studi Fase 1. Partisipan menyatakan bahwa pertanyaan jelas dan mudah 
dipahami. Untuk mengatasi kesulitan partisipan mengingat data yang ditanyakan, kami melakukan beberapa 
perubahan untuk mendapatkan data yang mungkin tidak terisi, misalnya dengan merujuk data pada rekam 
medis, membuat proxy biaya, dan memandu pewawancara untuk menanyakan harga tertentu jika partisipan 
tidak yakin harga perkiraan pasar dari barang yang mereka jual. Kesimpulan: ‘The Tool to Estimate Patient 
Costs’ yang diadaptasi dalam Bahasa Indonesia dinilai komprehensif, siap dipakai untuk studi lain tentang 
biaya katastrofik terkait TB dan untuk memonitor pencapaian target the End TB Strategy. 
Kata kunci: tuberkulosis, biaya pasien, biaya katastrofik, adaptasi, Indonesia.
ABSTRACT
Background: Indonesia is the second-highest country for tuberculosis (TB) incidence worldwide. Hence, 
it urgently requires improvements and innovations beyond the strategies that are currently being implemented 
throughout the country. One fundamental step in monitoring its progress is by preparing a validated tool to 
measure total patient costs and catastrophic total costs. The World Health Organization (WHO) recommends 
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using a version of the generic questionnaire that has been adapted to the local cultural context in order to 
interpret findings correctly. This study is aimed to adapt the Tool to Estimate Patient Costs questionnaire into the 
Indonesian context, which measures total costs and catastrophic total costs for tuberculosis-affected households. 
Methods: the tool was adapted using best-practice guidelines. On the basis of a pre-test performed in a previous 
study (referred to as Phase 1 Study), we refined the adaptation process by comparing it with the generic tool 
introduced by the WHO. We also held an expert committee review and performed pre-testing by interviewing 30 
TB patients. After pre-testing, the tool was provided with complete explanation sheets for finalization. Results: 
seventy-two major changes were made during the adaptation process including changing the answer choices 
to match the Indonesian context, refining the flow of questions, deleting questions, changing some words and 
restoring original questions that had been changed in Phase 1 Study. Participants indicated that most questions 
were clear and easy to understand. To address recall difficulties by the participants, we made some adaptations 
to obtain data that might be missing, such as tracking data to medical records, developing a proxy of costs and 
guiding interviewers to ask for a specific value when participants were uncertain about the estimated market 
value of property they had sold. Conclusion: the adapted Tool to Estimate Patient Costs in Bahasa Indonesia is 
comprehensive and ready for use in future studies on TB-related catastrophic costs and is suitable for monitoring 
progress to achieve the target of the End TB Strategy.
Keywords: tuberculosis, patient costs, catastrophic costs, adaptation, Indonesia.
INTRODUCTION
Indonesia is achieving slow progress in 
its struggle to eliminate tuberculosis (TB). 
With the world’s second-highest TB incidence 
worldwide,1 it urgently requires improvements 
and innovations beyond the strategies that are 
currently being implemented throughout the 
country. While training of healthcare workers is 
essential, it is also important to note that access to 
healthcare often brings financial hardship to TB 
patients. The most vulnerable are poor families, 
who must deal not only with medical costs, but 
also with non-medical costs, such as travel and 
supplementation costs, which can drain up to 
half of their annual income.2,3 All these costs are 
compounded by potential income loss.4
Challenges in eliminating TB therefore 
go beyond clinical management and are often 
related to socioeconomic problems. These 
problems can increase delay in TB diagnosis and 
treatment and plunge patients into a more severe 
state of TB illness and a higher risk of treatment 
failure and MDR-TB development.2–4 This, in 
turn, will lead to more complicated cases with 
substantial implications for clinical management. 
Clinicians should therefore consider the financial 
problems faced by TB patients and their affected 
families during consultations.
Many patients, because of embarrassment, 
prefer firstly to seek care from private providers 
rather than public health facilities, regardless 
of their financial capacity. Assessing patients’ 
financial capability will help clinicians to decide 
whether they can prescribe additional diagnostic 
tests such as X-ray and branded drugs that may be 
unaffordable for patients. Otherwise, they should 
refer patients to public health facilities linked 
to the National Tuberculosis Program (NTP) 
that provides free laboratory examinations and 
TB treatment. During TB treatment, clinicians 
should also assess whether patients can afford 
transportation costs before deciding the number 
of visits per month. Assessing all of these issues 
is important to increase patients’ adherence to the 
TB diagnostic procedures and treatment, as well 
as TB treatment success.
Understanding the complexity of TB 
burden, the End TB Strategy acknowledges the 
importance of these socioeconomic determinants 
in its target that by 2020, no TB-affected family 
should face catastrophic spending due to TB.5–7 
In some countries including Indonesia, it is very 
important that progress towards this target is 
monitored properly. One fundamental step in 
monitoring progress is preparing a validated tool 
for measuring total patient costs and catastrophic 
total costs. The World Health Organization 
(WHO) recommends using a version of the 
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generic questionnaire “The Tool to Estimate 
Patient Costs”7,8 (henceforth referred to as the 
Generic Tool) that has been adapted to the local 
cultural context in order to interpret findings 
correctly.9,10 Before Indonesia implemented 
Universal Health Coverage (UHC) in 2014, Van 
den Hof et al. had adapted the Generic Tool to be 
used in Indonesia and it was pretested in 2013 
study. For the sake of convenience, we refer to 
the study as the Phase 1 Study.11,12 However, the 
tool is no longer suitable with recent situation 
partly due to implementation of UHC and various 
answer categories in the Phase 1 tool including 
categories on health insurance and healthcare 
facilities.  Also, since the pretesting in the Phase 
1 Study involved only five multi-drug-resistant 
(MDR) TB patients, a larger sample size was 
needed to perfect the adaptation.
To monitor progress towards the target of 
eliminating catastrophic spending on TB in 
Indonesia, the present study aimed to pursue 
further adaptation of the questionnaire that had 
been developed in the Phase 1 Study.
METHODS
The adaptation of The Tool to Estimate 
Patient Costs questionnaire consisted of two 
phases. The first phase was  performed separately 
by van den Hof et al as a preliminary Indonesian 
study (the Phase 1 Study) in 2013.12 Our study, 
which was referred to henceforth as the Phase 2 
study, comprised the second phase of adapting 
the Generic Tool. Our study had a cross-sectional 
design and was conducted in 2016. In line with 
existing guidelines,13,14 the whole process of 
adaptation consisted of seven steps. While the 
Phase 1 Study went through all the steps from I to 
VII, our Phase 2 Study re-ran steps V to VII, i.e. 
production of the definitive Indonesian Language 
version of the Tool. (Figure 1)
Study Population
We interviewed 30 TB patients who had 
undergone at least one month of TB treatment 
in two sub-district Primary Health Centres 
(PHCs, Puskesmas), East Jakarta, which were 
Puskesmas Cakung and Puskesmas Jatinegara. 
Figure 1. Study design: adaptation of the Tool
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We tracked patients registered on the TB patient 
list and chose patients who met the inclusion 
criteria consecutively from the most recent date 
of treatment initiation. In PHC Cakung, we 
invited TB and MDR-TB patients to come to 
PHC and interviewed patients who were coming 
to the PHC consecutively. On three consecutive 
days, we interviewed 18 patients. In PHC 
Jatinegara, we made calls to the patients to make 
an appointment and visited them at home for an 
interview until 12 TB and MDR-TB patients had 
participated. If patient could not be interviewed 
because they were unable to communicate or not 
available at the time of interview, we asked their 
caregiver (termed “drug observer”) to participate 
in the study. The procedure brought the total 
number of interviewees to 30.
Phase 1 Study
The principal investigator of the Phase 1 Study 
was a researcher from the KNCV Tuberculosis 
Foundation in the Netherlands, where the 
Generic Tool was originally developed. The 
study was prepared in Indonesia together with 
local researchers, one of whom was appointed 
to prepare for the forward translation into 
Bahasa Indonesia. Various questions, such as 
insurance types, types of healthcare facility and 
reimbursement schemes, were adapted to the local 
context. To check for interpretation errors, the 
questionnaire was back-translated and then pre-
tested on five MDR-TB patients at Persahabatan 
Hospital, in Jakarta.11 Its clarity for patients and 
interviewers was tested. After the pre-testing, 
further adaptations were made culminating in 
the final version of the Phase 1 Study Tool. We 
obtained the final version and compared it with 
the English version of the Generic Tool.
Phase 2 Study 
In our Phase 2 Study, we further refined the 
adapted version of the Tool to current Indonesian 
context. Rather than going through all of the 
steps again, we used the Phase 1 Study Tool 
as a starting point for adaptation and began the 
process at step V (i.e. expert committee review). 
Before doing so, we contacted the researchers of 
the Phase 1 Study by telephone and email and 
asked their permission to use their version for 
further adaptation.
Expert Committee Review
The objective of the expert committee review 
(step V) was to check the content of the Tool once 
again. For the purpose, we held a meeting and 
invited key persons to discuss the Phase 1 Tool. 
Besides local researchers, the meeting included 
the following external experts: a pulmonologist 
specialized in infectious disease, a staff member 
from the Sub-Directorate for Tuberculosis at the 
Ministry of Health Republic of Indonesia and a 
psychometrics expert.
Before the meeting, the principal investigator, 
an Indonesian citizen, made a brief report in 
which he commented on questions and choices 
in the Generic Tool that remained uncertain or 
could be misinterpreted. The committee then 
compared the Generic Tool and the Phase 1 
Study Tool, focusing on various sections in the 
WHO protocol that would need to be adapted 
to the local context. The adaptations included 
provider type, the TB care-delivery model, socio-
demographic variables, net revenue from labour-
related activities, health insurance and social 
protection and household assets. In addition 
to revising these sections, the committee also 
checked the entire Generic Tool and suggested 
some changes to the Phase 1 Study Tool. This 
stage resulted in a penultimate Indonesian 
translation version of the tool.
Pre-testing
In a one-day training session before the 
pre-testing, we trained six medical students 
to interview 30 TB and MDR-TB patients or 
their caregiver (if the patient were unable or 
unavailable for interview) in two sub-district 
PHCs of East Jakarta. After each respondent 
had been interviewed, interviewers reported any 
difficulties they had encountered with regard 
to completing the tool or to the respondents’ 
understanding of the questions. The researchers 
also discussed the findings, made changes 
and formulated the final version of the Tool in 
Indonesian Language.
Final Version
After pretesting and refinement, we 
developed the final version of the Tool. We also 
provided comprehensive explanation sheets to 
guide the interview. 
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Ethics
Pre-testing the Tool was part of our main 
study, which assessed catastrophic total costs 
among TB-affected households. We had obtained 
ethical approval from the Ethical Committee of 
the Faculty of Medicine, Universitas Indonesia 
and Cipto Mangunkusumo Hospital (No. 416/
UN2.F1/ETIK/VI/2016) before commencing 
the study. Before the interview, we provided 
oral and written explanation to respondents and 
required them to sign informed consent forms. 
We ensured the confidentiality of all information 
collected from the interview.
RESULTS
In total, 72 major changes were made during 
the adaptation process from the Generic Tool to 
the final version of Phase 2 Study (see Annex). 
The adaptations consisted of the following: 
reformulating questions and choices to reflect 
the current Indonesian context; re-structuring the 
ordering of several questions; deleting certain 
questions from the Generic Tool; and later 
restoring questions which had previously been 
deleted in the Phase 1 Study.
Phase 1 Study involved 60 changes relative 
to the Generic Tool. As well as the addition of 
two question sets under new sub-topics (moving 
costs and adverse effect costs), these changes 
included changing question sets into table form, 
adding seven questions and one sub-question, 
altering five answer choices and two wordings, 
and deleting three question sets (sub-topics) and 
33 questions.
The most important change made in the 
Phase 1 Study was the overall flow of the Tool. 
In the Generic Tool, the questions are grouped 
on the basis of the types of cost. This required 
respondents to recall the costs they had incurred 
back and forth between the pre-diagnostic, 
diagnostic, and treatment phases. To facilitate 
the flow of interview, the Phase 1 Study had re-
arranged the flow to match the time sequence. 
Other prominent changes involved redesigning 
some questions into table form, which made 
it easier for the interviewers to ask them and 
thereby to complete the Tool. 
During the expert review meeting in Phase 
2 Study, we changed the answer choices 
relating to provider type from “Health Post (Pos 
Kesehatan)”, “PHC (Puskesmas), and “district 
hospital (RSUD)” to “PHC (Puskesmas)”, 
“private clinic”, “public hospital”, “private 
hospital”, and “other”. With reference to the 
TB delivery model, we changed the term 
“DOT” (Directly Observed Treatment), which 
respondents may not know, to “visit to take 
TB drugs” to make it easier for participants to 
understand the questions. In the section with 
socio-demographic questions, we changed 
categories relating to income payments (paid 
regularly, uncertain, paid in kind, not paid, 
and others). We also changed a question from 
“currently formally employed” to “formally 
employed before being diagnosed”, and followed 
with the question “Did you have to change or 
quit your employment after being diagnosed 
with TB?”. We restored a question “how many 
people regularly sleep in your household”, and 
modified it to “how many family members live 
in your household?”.
As UHC had been implemented in Indonesia 
since the Phase 1 study, the insurance system 
had changed. Using the abbreviation BPJS to 
indicate the national health insurance agency 
(Badan Penyelenggara Jaminan Sosial, BPJS), 
we adapted the types of insurance to government-
paid BPJS, self-paid BPJS, and private insurance. 
No changes were made to questions in the 
revenue section. However, we made changes 
in the costs section, including the type of 
supplement taken (“drinks” to “milk”); the 
frequency of taking supplementation (from “per 
month” to “per week”); and the coping section 
(by changing the order of the questions on the 
amount of money gained from selling property). 
We also changed some wordings to make it 
easier for participants to understand questions, 
for example changing the term “smear” to “Basil 
Tahan Asam (BTA)” or the Acid-Fast Bacili 
(AFB) testing, and “pengembalian asuransi” to 
“reimbursement asuransi”.
We retained 38 questions that were the result 
of adaptations made in the Phase 1 Study. We also 
restored 12 original questions from the Generic 
Tool that had been changed, and five original 
questions that had been deleted in the Phase 1 
Tool. The restored questions included “date of 
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first diagnostic examination”, “date of starting 
treatment”, “where did you seek treatment?”, 
“what symptoms did you experience?”, and 
“why didn’t you go to a public facility?”. We also 
deleted three questions and three answer choices 
that had been added in the Phase 1 Study.
Pre-testing
Seventy-four percent of the participants 
received the Category I therapy regimen; only 
7% took MDR therapy. The majority (63%) 
underwent TB treatment in the continuation 
phase. (Table 1)
added explanatory notes for interviewers in the 
interview guidance. Instead of asking these data 
to participants, interviewers should track the data 
in the patients’ medical records. Respondents 
had difficulty to estimate transportation costs if 
they used their own vehicle. To deal with that, 
we guided interviewers to ask transportation-
related costs such as parking or toll fees, but not 
fuel costs.
Many participants received bills from 
healthcare facilities that stated total amount 
of cost without any itemization. They had 
difficulty to distinguish between administration, 
laboratory, X-ray and drug costs. In such cases, 
we allowed interviewers to enter the total 
amount under administration costs. We deleted 
sub-questions under hospitalization costs and 
left only one question on total hospitalization 
costs since participants could not explain the 
detail of hospital item costs. If a TB patient had 
sold property and did not know the estimated 
market value, we added a question “Did the 
price conform to the estimated market value?” 
and trained interviewers to ask the specific price 
when participants were uncertain about the 
market value of property they had sold.
Annex 2 (available on www.actamedindones.
org) contains the final version of the questionnaire 
resulting from our Phase 2 study, along with the 
explanatory notes.
DISCUSSION
The Tool was successfully adapted to the 
current Indonesian context. It is now ready for 
use in similar studies on TB cost measurement 
and for monitoring progress to achieve the 
End TB Strategy target. Under the terms of the 
strategy, the government should monitor the 
target until 2035. Monitoring TB-related costs 
can help identify determinants of TB treatment 
outcomes and reduce the risk of treatment failure, 
severe adverse outcome, and further spread of 
TB, MDR-TB, or even XDR-TB because of 
socioeconomic problems.2,4,15–17
In our view, the adapted Tool is suitable for 
the purpose as it is more comprehensive than 
previous versions and is fully consistent with the 
situation in Indonesia since the implementation 
of UHC. The Tool can measure not only total 
Table 1. Subject’s characteristics
Variables n (%)
Participant
 - TB patients 27 (90.0)
 - Drug observers 3 (10.0)
Sex
 - Male 15 (50.0)
 - Female 15 (50.0)
Age category, years
 - 18-30 5 (17.0)
 - 31-40 6 (20.0)
 - 41-50 5 (17.0)
 - >50 14 (46.0)
Educational level
 - Low 10 (33.0)
 - Intermediate 20 (67.0)
Type of TB
 - Pulmonary, smear + 22 (73.0)
 - Pulmonary, smear - 7 (23.0)
 - Pulmonary, smear unknown 1 (4.0)
Therapy regimen
 - Cat I 22 (73.0)
 - Cat II 6 (20.0)
 - MDR 2 (7.0)
Therapy phase
 - Intensive phase 11 (37.0)
 - Continuation phase 19 (63.0)
The respondents indicated that the majority 
of questions were clear and easy to understand. 
However, they had problems answering some 
others. Most respondents forgot the date of 
their first TB examination (63%) and the date 
they started treatment (57%). Neither did they 
know their HIV status (53%). We therefore 
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costs, but – as recommended by the WHO – also 
catastrophic total costs.7
Besides the refinements made to the Phase 
1 version of the Tool, the strengths of this study 
include the relatively large number of respondents 
recruited, their wide age-range, and the balance 
between the sexes. The limitation is the fact 
that we only interviewed participants who were 
undergoing TB and MDR-TB treatment in PHCs. 
Thereby we excluded those who underwent TB 
treatment in other types of health facility or who 
dropped out of TB treatment. However, this 
limitation has been acknowledged in the WHO 
protocol, which excludes TB patients treated 
in facilities that are not linked to the national 
tuberculosis program. It means that the adapted 
Tool is now the most appropriate questionnaire 
for measuring catastrophic total costs.
The translation version that has been followed 
from the Phase 1 Study is acceptable and easily 
understood and there was no need for re-translation 
from English into Bahasa Indonesia. However, 
difficulties were encountered when we were 
seeking appropriate translations for terms such 
“DOT”, “dispensary”, and “mission hospital” 
that have no specific equivalent in Indonesian 
language, which may cause misunderstanding. 
Another potential source of misunderstanding was 
how participants define “primary income earner” 
or “pencari nafkah”, which may lead to confusion 
between “pencari nafkah” (primary income 
earner/breadwinner) and “kepala keluarga” (head 
of family). We therefore inserted an explanation 
of “primary income earner” as the highest earners 
who actually spent their earnings on financing the 
household.
In rural or remote areas of Indonesia where 
the Indonesian language is not being used in daily 
life, future studies should further adapt the Tool 
to the cultural context and local languages. It is 
imperative that all question items are explained 
clearly in the local languages.
The adaptation of the tool also provides useful 
insights for clinical practice. Instead of merely 
focusing on clinical complaints of TB patients, 
clinicians should also take socioeconomic 
problems into account, including the availability 
of health insurance, traveling costs to visit the 
health facility, and potential income or job loss 
faced by the patient and their families. Assessing 
patients’ financial capacity will help clinicians to 
decide on appropriate prescription, including any 
additional supplements needed. Clinicians may 
also refer patients to existing social protection 
programs, e.g., national health insurance or 
national employee insurance, if patients are 
uninsured, or refer them to primary health centers 
that provide TB diagnostic and treatment freely.
CONCLUSION
Our adapted version of the Tool to Estimate 
Patient Costs had been proven to be acceptable for 
use in Indonesia. Together with its explanations, 
it is easily understood by interviewers and 
interviewees. It is also ready for use in future 
studies on tuberculosis-related cost estimation 
and catastrophic spending measurement. 
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